NasdaqGS - Nasdaq Real Time Price USD

Apellis Pharmaceuticals, Inc. (APLS)

41.06 +1.81 (+4.60%)
As of 10:34 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
524,070.00
396,591.00
75,422.00
66,563.00
250,646.00
--
Cost of Revenue
70,910.00
58,510.00
5,636.00
5,200.00
25,050.00
--
Gross Profit
453,160.00
338,081.00
69,786.00
61,363.00
225,596.00
--
Operating Expense
857,288.00
855,202.00
664,399.00
597,640.00
439,322.00
--
Operating Income
-404,128.00
-517,121.00
-594,613.00
-536,277.00
-213,726.00
--
Net Non Operating Interest Income Expense
-10,176.00
-8,648.00
-23,712.00
-12,823.00
-25,773.00
--
Other Income Expense
-949.00
-727.00
-33,178.00
-196,902.00
-103,530.00
--
Pretax Income
-415,253.00
-526,496.00
-651,503.00
-746,002.00
-343,029.00
--
Tax Provision
2,020.00
2,132.00
669.00
352.00
1,845.00
--
Net Income Common Stockholders
-417,273.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
--
Diluted NI Available to Com Stockholders
-417,273.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
--
Basic EPS
-3.43
-4.45
-6.15
-8.84
-4.59
--
Diluted EPS
-3.43
-4.45
-6.15
-8.84
-4.59
--
Basic Average Shares
120,949.25
118,678.00
106,114.00
84,421.00
75,163.00
--
Diluted Average Shares
120,949.25
118,678.00
106,114.00
84,421.00
75,163.00
--
Total Operating Income as Reported
-404,128.00
-517,121.00
-594,613.00
-536,277.00
-213,726.00
--
Total Expenses
928,198.00
913,712.00
670,035.00
602,840.00
464,372.00
--
Net Income from Continuing & Discontinued Operation
-417,273.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
--
Normalized Income
-417,273.00
-528,628.00
-626,188.90
-601,621.28
-269,662.83
--
Interest Income
18,843.00
20,933.00
8,914.00
418.00
4,164.00
--
Interest Expense
29,019.00
29,581.00
32,626.00
13,241.00
29,937.00
--
Net Interest Income
-10,176.00
-8,648.00
-23,712.00
-12,823.00
-25,773.00
--
EBIT
-386,234.00
-496,915.00
-618,877.00
-732,761.00
-313,092.00
--
EBITDA
-384,601.00
-495,211.00
-617,390.00
-731,269.00
-312,233.00
--
Reconciled Cost of Revenue
70,910.00
58,510.00
5,636.00
5,200.00
25,050.00
--
Reconciled Depreciation
1,633.00
1,704.00
1,487.00
1,492.00
859.00
--
Net Income from Continuing Operation Net Minority Interest
-417,273.00
-528,628.00
-652,172.00
-746,354.00
-344,874.00
--
Total Unusual Items Excluding Goodwill
--
--
-32,890.00
-198,264.00
-103,029.00
--
Total Unusual Items
--
--
-32,890.00
-198,264.00
-103,029.00
--
Normalized EBITDA
-384,601.00
-495,211.00
-584,500.00
-533,005.00
-209,204.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
--
--
-6,906.90
-53,531.28
-27,817.83
--
12/31/2019 - 11/9/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYTK Cytokinetics, Incorporated
49.69
+2.43%
 
ARGX argenx SE
376.36
+1.44%
 
IMVT Immunovant, Inc.
25.80
+1.61%
 
BBIO BridgeBio Pharma, Inc.
29.44
+5.11%
 
BHVN Biohaven Ltd.
35.82
+2.05%
 
MDGL Madrigal Pharmaceuticals, Inc.
241.90
+2.43%
 
BPMC Blueprint Medicines Corporation
106.98
+1.35%
 
DYN Dyne Therapeutics, Inc.
31.59
-0.93%
 
LEGN Legend Biotech Corporation
39.47
-1.36%
 
IMCR Immunocore Holdings plc
44.55
-9.04%